Skip to main content

Coherus Bio(CHRS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Coherus Highlights Anticipated New Product Launches and Immuno-oncology Growth Strategy at Analyst Day Event

Globe Newswire - Tue Mar 29, 2022

— Multiple near-term anticipated product launches and development of innovative immuno-oncology pipeline position Coherus for long-term growth –

— Introducing 2026 revenue target of $1.2 billion in annual net sales from Coherus' diversified product portfolio –

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe